Diffusion Pharmaceuticals is developing new drugs which help regulate the movement of oxygen into tissue by a novel mechanism of action. Because oxygen is fundamental to life’s processes, these drugs offer promising new treatments for a host of life-threatening diseases, including cancer, stroke, and heart attack. Our lead drug, trans sodium crocetinate (TSC), uses this mechanism to sensitize cancerous cells to the tumor killing power of radiation therapy.
Diffusion Presentation at the United Nations
On May 4, 2014, David Kalergis, CEO of Diffusion Pharmaceuticals LLC, addressed The Global Health Impact Forum at the General Assembly Building of the United Nations. His talk was on “Improving the Treatment of Cancer by Targeting Hypoxia,” and included a video interview with brain cancer patient Stephen Clark. By vote of the conference attendees, the Diffusion Pharmaceuticals contribution was awarded “Best Presentation” and guaranteed an invitation to speak at the follow-on conference to be held at Oxford University, England. Diffusion Pharmaceuticals LLC is now engaged in discussions with representatives of the pharmaceutical industry to help speed the development of its novel technology for cancer and other life-saving uses.
Press Play Button Below To Watch Video